Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
2.
J Nephrol ; 34(6): 2093-2097, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34031847

RESUMO

INTRODUCTION: Estimated dry weight is used to guide fluid removal during outpatient hemodialysis sessions. Errors in estimated dry weight can result in intradialytic hypotension and interdialytic fluid overload. The goal of this study was to assess the accuracy of estimated dry weight by comparing it to the 2-week post-transplant weight in two cohorts of hemodialysis patients. METHODS: This observational, multi-center, retrospective cohort study included maintenance hemodialysis patients who underwent kidney transplantation at two medical centers in Massachusetts. The relationship between estimated dry weight pre-transplant and weight at week 2 post-transplant in patients with good allograft function (serum creatinine ≤ 1.5 mg/dL) was analyzed. Estimated dry weight was considered accurate if it was within ± 2% of the week 2 post-transplant weight. RESULTS: Fifty seven patients with good allograft function were identified: mean age 54 ± 14 years, 32 (58%) from deceased donors, 22 (38.6%) females. 38 were Caucasian (66.7%), 11 Hispanic (19.3%), 3 black (5.3%), and 5 others (8.8%). 2-week mean post transplantation serum creatinine was 1.2 ± 0.2 mg/dL. Mean (SD) estimated dry weight was 71.4 ± 15.9. Before transplantation, only 14 (24.6%) patients were within ± 2% of the 2-week post-transplant weight; 23 (40.3%) were above and 20 (35.1%) were below. CONCLUSIONS: Our point of view, based on the assumption that the weight of patients with good allograft function at 2 weeks post-transplant approaches their accurate dry weight, is that a majority of maintenance hemodialysis patients (75.4%) are hypervolemic or hypovolemic prior to renal transplantation. This highlights the importance of finding novel tools to achieve euvolemia in patients undertaking dialysis. Timely feedback regarding achieved weight 2 weeks post-transplant to treating nephrologists and dialysis centers may be a starting point for assessing accuracy of dry weight.


Assuntos
Falência Renal Crônica , Transplante de Rim , Adulto , Idoso , Feminino , Humanos , Rim , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/terapia , Transplante de Rim/efeitos adversos , Pessoa de Meia-Idade , Diálise Renal , Estudos Retrospectivos
3.
Ann Thorac Surg ; 112(2): 532-538, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33137299

RESUMO

BACKGROUND: The urinary cell cycle arrest biomarkers (UBs) insulin-like growth factor-binding protein-7 and tissue inhibitor of metalloproteinases-2 provide early detection of kidney stress, and elevations may predict cardiac surgery-associated acute kidney injury (CS-AKI). We sought to determine whether known clinical risk factors for CS-AKI correlated with increased UB values. METHODS: UBs were measured over a 12-month period the morning after on-pump cardiac surgery. Patients with a preoperative serum creatinine level greater than 2.0 mg/dL or patients undergoing dialysis were excluded. Known clinical AKI risk factors in patients with elevated UB (>0.3 (ng/mL)2/1000), that is known to correlate with kidney stress, were compared with patients with low scores (≤0.3 (ng/mL)2/1000) by using logistic regression; the analysis was repeated with UB as a continuous variable. RESULTS: A total of 412 patients met inclusion criteria. Unadjusted results demonstrated a clinically similar CS-AKI risk profile in patients with either elevated or low UB values. The Pearson correlation between preoperative estimated glomerular filtration rate and UB was low (r = 0.16). Clinical risk factors for CS-AKI were not associated with elevated UB values in the logistic regression model, thus producing an area under the receiver operating characteristic curve of 0.63. Linear regression analysis also found few associations between CS-AKI clinical risk factors and UB when measured as a continuous variable, (R2) = 0.15. CONCLUSIONS: Traditional CS-AKI clinical risk factors do not differ between patients with normal or elevated UB values. This UB test may identify patients at increased risk for AKI who otherwise would appear to be at low risk by traditional metrics.


Assuntos
Injúria Renal Aguda/sangue , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Diagnóstico Precoce , Taxa de Filtração Glomerular/fisiologia , Complicações Pós-Operatórias , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/etiologia , Idoso , Biomarcadores/sangue , Feminino , Seguimentos , Humanos , Masculino , Estudos Prospectivos , Curva ROC , Fatores de Risco
4.
J Pediatr Hematol Oncol ; 42(7): e668-e669, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-31343485

RESUMO

Ectopic adrenocorticotropic hormone syndrome is a paraneoplastic phenomenon rarely seen in pediatrics and rarely described in Ewing sarcoma. We report a 15-year-old boy with abdominal Ewing sarcoma and clinical and laboratory findings of ectopic adrenocorticotropic hormone syndrome that promptly resolved with treatment of the tumor.


Assuntos
Síndrome de ACTH Ectópico/patologia , Neoplasias Abdominais/complicações , Neoplasias Ósseas/complicações , Sarcoma de Ewing/complicações , Síndrome de ACTH Ectópico/etiologia , Síndrome de ACTH Ectópico/terapia , Neoplasias Abdominais/patologia , Adolescente , Hormônio Adrenocorticotrópico/metabolismo , Neoplasias Ósseas/patologia , Humanos , Masculino , Prognóstico , Sarcoma de Ewing/patologia
5.
J Thorac Cardiovasc Surg ; 160(5): 1235-1246.e2, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-31757451

RESUMO

BACKGROUND: Prediction of acute kidney injury (AKI) following cardiac surgery is unreliable through the use of serum creatinine or urinary output alone. Cell cycle arrest urinary biomarkers insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP2) provide early detection of kidney stress and possibly AKI. We sought to determine whether therapeutic interventions driven by elevated urinary biomarkers (UB) reduces post-cardiac surgery stage 2/3 AKI. METHODS: A quality improvement initiative based on UB was undertaken in all adult on-pump cardiac surgical patients with a preoperative serum creatinine level ≤2.0 mg/dL. A UB score the morning after cardiac surgery that was considered positive for kidney stress (≥0.3 [ng/mL]2/1000) triggered activation of a multidisciplinary acute kidney response team (AKRT) with implementation of a predefined staged protocol, including targeted goal-directed fluid management, liberalized transfusion thresholds, continued invasive hemodynamic monitoring and its optimization in the intensive care unit, and avoidance of nephrotoxins. We compared the incidence of stage 2/3 AKI before (pre-UB) versus after (post-UB) implementation of the Kidney Disease: Improving Global Outcomes quality improvement initiative. Standardized, protocolized, evidence-based care pathways were used pre-UB. RESULTS: The incidence of stage 2/3 AKI was compared in 435 pre-UB patients and 412 post-UB patients. Fifty-five percent of the post-UB patients had a moderate or high UB score (≥0.3 [ng/mL]2/1000). Ten patients (2.30%) had stage 2/3 AKI pre-UB, compared with 1 patient (0.24%) post-UB, a relative reduction of 89% (P = .01). The total and postoperative lengths of stay, cost, mortality, and readmissions were similar in the 2 groups. The negative predictive value for AKI of UB <0.3 [ng/mL]2/1000 was 100%. CONCLUSIONS: The routine measurement of UB and subsequent activation of an AKRT are useful post-cardiac surgery therapeutic adjuncts. They are associated with early detection of kidney stress, allowing for targeted proactive intervention, and a significant decrease in postoperative stage 2/3 AKI without increases in cost or length of stay.


Assuntos
Injúria Renal Aguda , Biomarcadores/urina , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Complicações Pós-Operatórias , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/epidemiologia , Injúria Renal Aguda/terapia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/terapia , Estudos Retrospectivos
6.
Int J Nephrol Renovasc Dis ; 12: 49-58, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30962703

RESUMO

BACKGROUND: Data derived from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study were analyzed in an effort to employ machine learning methods to predict the composite endpoint described in the original study. METHODS: We identified 573 CORAL subjects with complete baseline data and the presence or absence of a composite endpoint for the study. These data were subjected to several models including a generalized linear (logistic-linear) model, support vector machine, decision tree, feed-forward neural network, and random forest, in an effort to attempt to predict the composite endpoint. The subjects were arbitrarily divided into training and testing subsets according to an 80%:20% distribution with various seeds. Prediction models were optimized within the CARET package of R. RESULTS: The best performance of the different machine learning techniques was that of the random forest method which yielded a receiver operator curve (ROC) area of 68.1%±4.2% (mean ± SD) on the testing subset with ten different seed values used to separate training and testing subsets. The four most important variables in the random forest method were SBP, serum creatinine, glycosylated hemoglobin, and DBP. Each of these variables was also important in at least some of the other methods. The treatment assignment group was not consistently an important determinant in any of the models. CONCLUSION: Prediction of a composite cardiovascular outcome was difficult in the CORAL population, even when employing machine learning methods. Assignment to either the stenting or best medical therapy group did not serve as an important predictor of composite outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00081731.

7.
Plants (Basel) ; 7(4)2018 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-30463212

RESUMO

In the past years, the diversity of Capsicum has been mainly investigated through genetics and genomics approaches, fewer efforts have been made in the field of plant phenomics. Assessment of crop traits with high-throughput methodologies could enhance the knowledge of the plant phenome, giving at the same time a key contribution to the understanding of the function of many genes. In this study, a wide germplasm collection of 307 accessions retrieved from 48 world regions, and belonging to nine Capsicum species was characterized for 54 plant, leaf, flower and fruit traits. Conventional descriptors and semi-automated tools based on image analysis and colour coordinate detection were used. Significant differences were found among accessions, between species and between sweet and spicy cultivated types, revealing a large diversity. The results highlighted how the domestication process and the continued selection have increased the variability of fruit shape and colour. Hierarchical clustering based on conventional and fruit morphological descriptors reflected the separation of species on the basis of their phylogenetic relationships. These observations suggested that the flow between distinct gene pools could have contributed to determine the similarity of the species on the basis of morphological plant and fruit parameters. The approach used represents the first high-throughput phenotyping effort in Capsicum spp. aimed at broadening the knowledge of the diversity of domesticated and wild peppers. The data could help to select best the candidates for breeding and provide new insight into the understanding of the genetic base of the fruit shape of pepper.

8.
Clin Nephrol ; 87 (2017)(3): 124-133, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28128726

RESUMO

Iron stores assuring optimal efficacy/safety for erythropoiesis are unknown in the dialysis population. Using multicenter trial data, we related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous iron dosing to achieved iron stores in 441 subjects randomized 2 : 1 to ferric citrate or active control as their phosphate binder over 52 weeks. Intravenous iron was given at each site's discretion if ferritin ≤ 1,000 ng/mL and transferrin saturation ≤ 30%. Multivariable time-dependent Cox regression jointly related the primary safety outcome (composite of cardiac, infection, gastrointestinal, and hepatobiliary serious adverse events) to moving averages of ferritin and transferrin saturation over the preceding 90 days with covariate adjustment. Multivariable generalized estimating equations related elevated ESA and intravenous iron doses to trailing 90-day averages of ferritin and transferrin saturation with covariate adjustment. The adjusted hazard ratio for the safety composite per 10% increase in transferrin saturation was 0.84 (95% confidence interval 0.68 - 1.02, p = 0.08) and 1.09 (0.86 - 1.35, p = 0.48) per 400 ng/mL increase in ferritin. The adjusted hazard ratio for the safety composite was 0.50 (0.29 - 0.88, p = 0.016) for the highest transferrin saturation tertile vs. the lowest. Adjusted odds ratios for higher intravenous iron dose were lower in the highest (0.23 [0.16 - 0.35], p < 0.001) and middle transferrin saturation tertile (0.42 [0.31 - 0.57], p < 0.001) vs. lowest. Incidence of elevated ESA dose was lower in the highest transferrin saturation tertile (p = 0.01). Ferritin did not predict clinical events or ESA dose. Transferrin saturation may be a better marker than serum ferritin to judge optimal iron stores in dialysis patients. Transferrin saturations > 34% are safe and provide maximal efficacy.
.


Assuntos
Eritropoese/efeitos dos fármacos , Compostos Férricos/uso terapêutico , Hematínicos/uso terapêutico , Diálise Renal/métodos , Administração Intravenosa , Adulto , Idoso , Feminino , Compostos Férricos/administração & dosagem , Ferritinas/sangue , Hematínicos/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Fosfatos/sangue
9.
Clin J Am Soc Nephrol ; 12(3): 524-535, 2017 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-27895136

RESUMO

Despite improvements in hypertension awareness and treatment, 30%-60% of hypertensive patients do not achieve BP targets and subsequently remain at risk for target organ damage. This therapeutic gap is particularly important to nephrologists, who frequently encounter treatment-resistant hypertension in patients with CKD. Data are limited on how best to treat patients with CKD and resistant hypertension, because patients with CKD have historically been excluded from hypertension treatment trials. First, we propose a consistent definition of resistant hypertension as BP levels confirmed by both in-office and out-of-office measurements that exceed appropriate targets while the patient is receiving treatment with at least three antihypertensive medications, including a diuretic, at dosages optimized to provide maximum benefit in the absence of intolerable side effects. Second, we recommend that each patient undergo a standardized, stepwise evaluation to assess adherence to dietary and lifestyle modifications and antihypertensive medications to identify and reduce barriers and discontinue use of substances that may exacerbate hypertension. Patients in whom there is high clinical suspicion should be evaluated for potential secondary causes of hypertension. Evidence-based management of resistant hypertension is discussed with special considerations of the differences in approach to patients with and without CKD, including the specific roles of diuretics and mineralocorticoid receptor antagonists and the current place of emerging therapies, such as renal denervation and baroreceptor stimulation. We endorse use of such a systematic approach to improve recognition and care for this vulnerable patient group that is at high risk for future kidney and cardiovascular events.


Assuntos
Vasoespasmo Coronário/diagnóstico , Vasoespasmo Coronário/terapia , Hipertensão/diagnóstico , Hipertensão/terapia , Cooperação do Paciente , Insuficiência Renal Crônica/complicações , Anti-Hipertensivos/uso terapêutico , Vasoespasmo Coronário/complicações , Vasoespasmo Coronário/epidemiologia , Dieta , Diuréticos/uso terapêutico , Quimioterapia Combinada , Terapia por Estimulação Elétrica , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Estilo de Vida , Antagonistas de Receptores de Mineralocorticoides/uso terapêutico , Simpatectomia
10.
Hemodial Int ; 21(2): 243-249, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27615161

RESUMO

INTRODUCTION: Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown. METHODS: We conducted a post-hoc analysis to evaluate whether adherence rates were different for ferric citrate vs. active control in 412 subjects with end stage kidney disease (ESKD) who were randomized to ferric citrate vs. active control (sevelamer carbonate and/or calcium acetate). Adherence was defined as percent of actual number of pills taken to total number of pills prescribed. FINDINGS: There were no significant differences in baseline characteristics including gender, race/ethnicity, and age between the ferric citrate and active control groups. Baseline phosphorus, calcium, and parathyroid hormone levels were similar. Mean (SD) adherence was 81.4% (17.4) and 81.7% (15.9) in the ferric citrate and active control groups, respectively (P = 0.88). Adherence remained similar between both groups after adjusting for gender, race/ethnicity, age, cardiovascular disease (CVD), and diabetic nephropathy (mean [95% CI]: 81.4% [78.2, 84.6] and 81.5% [77.7, 85.2] for ferric citrate and active control, respectively). Gender, race/ethnicity, age, and diagnosis of diabetic nephropathy did not influence adherence to the prescribed phosphate binder. Subjects with CVD had lower adherence rates to phosphate binder; this was significant only in the active control group. DISCUSSION: Adherence rates to the phosphate binder, ferric citrate, were similar to adherence rates to active control. Similar adherence rates to ferric citrate are notable since tolerance to active control was an entry criteria and the study was open label. Gender, race/ethnicity, nor age influenced adherence.


Assuntos
Quelantes/uso terapêutico , Compostos Férricos/uso terapêutico , Falência Renal Crônica/terapia , Diálise Renal/métodos , Feminino , Compostos Férricos/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade
11.
J Agric Food Chem ; 64(29): 5824-36, 2016 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-27357913

RESUMO

Rocket salad (Diplotaxis spp., Eruca spp.) is a leafy vegetable rich in health-promoting compounds and widely consumed. In the present study, metabolic profiles of 40 rocket accessions mainly retrieved from gene banks were assessed. Seven glucosinolates (GLSs) and 15 flavonol compounds were detected across genotypes. Dimeric 4-mercaptobutyl-GLS and 4-(ß-d-glucopyranosyldisulfanyl)butyl-GLS were the major components of the total glucosinolate content. Flavonols were different between genera, with the exception of isorhamnetin 3,4'-diglucoside. Morphoagronomic traits and color coordinates were also scored. Results showed a negative correlation between color and GLSs, indicating these last as responsible for the increase of the intensity of green and yellow pigments as well as for the darkness of the leaf, whereas agronomic traits showed positive correlation with GLSs. Genetic diversity was assessed using inter simple sequence repeat (ISSR) markers, allowing separation of the accessions on the basis of the species and elucidating the observations made by means of phenotypic data.


Assuntos
Brassicaceae/genética , Brassicaceae/metabolismo , Glucosinolatos/metabolismo , Folhas de Planta/crescimento & desenvolvimento , Brassicaceae/química , Brassicaceae/crescimento & desenvolvimento , Flavonóis/análise , Flavonóis/metabolismo , Glucosinolatos/análise , Folhas de Planta/química , Folhas de Planta/genética , Folhas de Planta/metabolismo
12.
Clin J Am Soc Nephrol ; 11(7): 1180-1188, 2016 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-27225988

RESUMO

BACKGROUND AND OBJECTIVES: Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (from May of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage ≥3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (≥30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. RESULTS: eGFR was 59±24 ml/min per 1.73 m(2) (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was -1.5±7.0 ml/min per 1.73 m(2) per year in the stent group versus -2.3±6.3 ml/min per 1.73 m(2) per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, and HDL cholesterol (positive associations). CKD outcomes events occurred in 19% (175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). CONCLUSIONS: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.


Assuntos
Doenças Cardiovasculares/etiologia , Taxa de Filtração Glomerular , Obstrução da Artéria Renal/fisiopatologia , Obstrução da Artéria Renal/terapia , Insuficiência Renal Crônica/fisiopatologia , Stents , Fatores Etários , Idoso , Albuminúria/etiologia , Antagonistas de Receptores de Angiotensina/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Aterosclerose/complicações , Aterosclerose/tratamento farmacológico , Pressão Sanguínea , HDL-Colesterol/sangue , Feminino , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Estimativa de Kaplan-Meier , Falência Renal Crônica/fisiopatologia , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Modelos de Riscos Proporcionais , Obstrução da Artéria Renal/etiologia , Insuficiência Renal Crônica/complicações , Fatores Sexuais , Abandono do Hábito de Fumar
13.
Cell Rep ; 13(7): 1353-1365, 2015 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-26549453

RESUMO

The basal ganglia play a critical role in shaping motor behavior. For this function, the activity of medium spiny neurons (MSNs) of the striatonigral and striatopallidal pathways must be integrated. It remains unclear whether the activity of the two pathways is primarily coordinated by synaptic plasticity mechanisms. Using a model of Parkinson's disease, we determined the circuit and behavioral effects of concurrently regulating cell-type-specific forms of corticostriatal long-term synaptic depression (LTD) by inhibiting small-conductance Ca(2+)-activated K(+) channels (SKs) of the dorsolateral striatum. At striatopallidal synapses, SK channel inhibition rescued the disease-linked deficits in endocannabinoid (eCB)-dependent LTD. At striatonigral cells, inhibition of these channels counteracted a form of adenosine-mediated LTD by activating the ERK cascade. Interfering with eCB-, adenosine-, and ERK signaling in vivo alleviated motor abnormalities, which supports that synaptic modulation of striatal pathways affects behavior. Thus, our results establish a central role of coordinated synaptic plasticity at MSN subpopulations in motor control.


Assuntos
Corpo Estriado/patologia , Plasticidade Neuronal , Substância Negra/patologia , Adenosina/fisiologia , Animais , Córtex Cerebral/citologia , Córtex Cerebral/patologia , Dopamina/fisiologia , Neurônios Dopaminérgicos/fisiologia , Potenciais Pós-Sinápticos Excitadores , Depressão Sináptica de Longo Prazo , Sistema de Sinalização das MAP Quinases , Camundongos , Atividade Motora , Doença de Parkinson Secundária/induzido quimicamente , Doença de Parkinson Secundária/patologia , Receptor A1 de Adenosina/metabolismo , Canais de Potássio Ativados por Cálcio de Condutância Baixa/metabolismo
14.
J Am Soc Nephrol ; 26(10): 2578-87, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25736045

RESUMO

Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic parameters and iv iron/ESA use at time points throughout the active control period of a phase 3 international randomized clinical trial. In all, 441 subjects were randomized (292 to FC and 149 to sevelamer carbonate and/or calcium acetate [active control (AC)]) and followed for 52 weeks. Subjects on FC had increased ferritin and transferrin saturation (TSAT) levels compared with subjects on AC by week 12 (change in ferritin, 114.1±29.35 ng/ml; P<0.001; change in TSAT, 8.62%±1.57%; P<0.001). Change in TSAT plateaued at this point, whereas change in ferritin increased through week 24, remaining relatively stable thereafter. Subjects on FC needed less iv iron compared with subjects on AC over 52 weeks (median [interquartile range] dose=12.9 [1.0-28.9] versus 26.8 [13.4-47.6] mg/wk; P<0.001), and the percentage of subjects not requiring iv iron was higher with FC (P<0.001). Cumulative ESA over 52 weeks was lower with FC than AC (median [interquartile range] dose=5303 [2023-9695] versus 6954 [2664-12,375] units/wk; P=0.04). Overall, 90.3% of subjects on FC and 89.3% of subjects on AC experienced adverse events. In conclusion, treatment with FC as a phosphate binder results in increased iron parameters apparent after 12 weeks and reduces iv iron and ESA use while maintaining hemoglobin over 52 weeks, with a safety profile similar to that of available binders.


Assuntos
Anemia/tratamento farmacológico , Compostos Férricos/uso terapêutico , Hematínicos/administração & dosagem , Ferro/administração & dosagem , Administração Intravenosa , Anemia/etiologia , Quimioterapia Combinada , Feminino , Humanos , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade
15.
Cereb Cortex ; 25(10): 3356-68, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24962993

RESUMO

Idiopathic epilepsies have frequently been linked to mutations in voltage-gated channels (channelopathies); recently, mutations in several genes encoding presynaptic proteins have been shown to cause epilepsy in humans and mice, indicating that epilepsy can also be considered a synaptopathy. However, the functional mechanisms by which presynaptic dysfunctions lead to hyperexcitability and seizures are not well understood. We show that deletion of synapsin II (Syn II), a presynaptic protein contributing to epilepsy predisposition in humans, leads to a loss of tonic inhibition in mouse hippocampal slices due to a dramatic decrease in presynaptic asynchronous GABA release. We also show that the asynchronous GABA release reduces postsynaptic cell firing, and the parallel impairment of asynchronous GABA release and tonic inhibition results in an increased excitability at both single-neuron and network levels. Restoring tonic inhibition with THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; gaboxadol), a selective agonist of δ subunit-containing GABAA receptors, fully rescues the SynII(-/-) epileptic phenotype both ex vivo and in vivo. The results demonstrate a causal relationship between the dynamics of GABA release and the generation of tonic inhibition, and identify a novel mechanism of epileptogenesis generated by dysfunctions in the dynamics of release that can be effectively targeted by novel antiepileptic strategies.


Assuntos
Hipocampo/fisiologia , Inibição Neural , Neurônios/fisiologia , Sinapsinas/fisiologia , Ácido gama-Aminobutírico/fisiologia , Potenciais de Ação/efeitos dos fármacos , Animais , Potenciais Pós-Sinápticos Excitadores , Agonistas GABAérgicos/farmacologia , Hipocampo/efeitos dos fármacos , Hipocampo/fisiopatologia , Potenciais Pós-Sinápticos Inibidores , Isoxazóis/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Neurônios/efeitos dos fármacos , Convulsões/fisiopatologia , Sinapsinas/genética
16.
Nephron ; 129(1): 22-8, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25532068

RESUMO

BACKGROUND/AIMS: Pyridoxamine dihydrochloride (Pyridorin™) blocks pathogenic oxidative pathways in the progression of diabetic nephropathy. The pyridoxamine pilot study was designed to test entry criteria and outcomes. Subjects had SCr 1.3-3.5 mg/dl, protein-to-creatinine ≥1,200 mg/g and used a surrogate outcome of ΔSCr over 52 weeks. Subjects had to be on a maximally tolerated dose of ACE/ARB for 3 months; stable other antihypertensive doses for 2 months; stable diuretic dose for 2 weeks, and BP ≤160/90 mm Hg; or enter a Pharmaco-Stabilization Phase (PSP). This pilot failed to detect an effect on ΔSCr in intent-to-treat analysis. METHODS: We queried the locked clinical trial database for subgroups in which there was a treatment effect. RESULTS: Subjects not requiring PSP and those with entry SCr <2.0 mg/dl had a treatment effect. Subjects entering PSP required more changes in antihypertensive medications and experienced larger ΔSCr over 52 weeks. PSP subjects with BP >140/90 mm Hg had no treatment effect, but those ≤140/90 mm Hg did. CONCLUSION: Time required for acute effects of ACE/ARB to stabilize is unknown, but these data suggest >3 months. Thus, subjects in the pivotal trial must be on ACE/ARB for 6 months. Frequent antihypertensive adjustment could engender SCr changes unrelated to CKD progression. Thus, we will require subjects to have BP ≤150/90 mm Hg and on stable antihypertensives for 26 weeks, or ≤140/90 mm Hg and on stable antihypertensives for 13 weeks. Since ΔSCr over 52 weeks is limited as a surrogate outcome, the pivotal trial uses a time-to-event analysis of baseline SCr to at least a 50% increase in SCr or ESRD as the primary outcome. This substantial ΔSCr is protected from noise and is clinically relevant. The pyridoxamine pilot provided critical information to inform the design of PIONEER-CSG-17, which we conducted under the SPA agreement with FDA.


Assuntos
Antioxidantes/uso terapêutico , Nefropatias Diabéticas/tratamento farmacológico , Piridoxamina/análogos & derivados , Idoso , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Anti-Hipertensivos/administração & dosagem , Antioxidantes/administração & dosagem , Creatinina/sangue , Diabetes Mellitus Tipo 2/complicações , Nefropatias Diabéticas/sangue , Diuréticos/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Masculino , Projetos Piloto , Piridoxamina/administração & dosagem , Piridoxamina/uso terapêutico
18.
Eur J Neurosci ; 39(7): 1189-201, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24712998

RESUMO

Synaptic neuromodulation acts across different functional domains to regulate cognitive processing and behavior. Recent challenges are related to elucidating the molecular and cellular mechanisms through which neuromodulatory pathways act on multiple time scales to signal state-dependent contingencies at the synaptic level or to stabilise synaptic connections during behavior. Here, we present a framework with the synaptic neuromodulators endocannabinoids (eCBs) as key players in dynamic synaptic changes. Modulation of various molecular components of the eCB pathway yields interconnected functional activation states of eCB signaling (prior, tonic, and persistent), which may contribute to metaplastic control of synaptic and behavioral functions in health and disease. The emerging picture supports aberrant metaplasticity as a contributor to cognitive dysfunction associated with several pathological states in which eCB signaling, or other neuromodulatory pathways, are deregulated.


Assuntos
Endocanabinoides/metabolismo , Plasticidade Neuronal , Sinapses/metabolismo , Transmissão Sináptica , Animais , Humanos , Sinapses/fisiologia
19.
J Clin Invest ; 124(4): 1468-82, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24614104

RESUMO

The recent identification of multiple dominant mutations in the gene encoding ß-catenin in both humans and mice has enabled exploration of the molecular and cellular basis of ß-catenin function in cognitive impairment. In humans, ß-catenin mutations that cause a spectrum of neurodevelopmental disorders have been identified. We identified de novo ß-catenin mutations in patients with intellectual disability, carefully characterized their phenotypes, and were able to define a recognizable intellectual disability syndrome. In parallel, characterization of a chemically mutagenized mouse line that displays features similar to those of human patients with ß-catenin mutations enabled us to investigate the consequences of ß-catenin dysfunction through development and into adulthood. The mouse mutant, designated batface (Bfc), carries a Thr653Lys substitution in the C-terminal armadillo repeat of ß-catenin and displayed a reduced affinity for membrane-associated cadherins. In association with this decreased cadherin interaction, we found that the mutation results in decreased intrahemispheric connections, with deficits in dendritic branching, long-term potentiation, and cognitive function. Our study provides in vivo evidence that dominant mutations in ß-catenin underlie losses in its adhesion-related functions, which leads to severe consequences, including intellectual disability, childhood hypotonia, progressive spasticity of lower limbs, and abnormal craniofacial features in adults.


Assuntos
Anormalidades Craniofaciais/genética , Deficiência Intelectual/genética , Mutação , beta Catenina/genética , Adolescente , Adulto , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Sequência de Bases , Encéfalo/patologia , Caderinas/química , Pré-Escolar , Anormalidades Craniofaciais/patologia , DNA/genética , Modelos Animais de Doenças , Feminino , Genes Dominantes , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Mutantes , Pessoa de Meia-Idade , Modelos Moleculares , Dados de Sequência Molecular , Complexos Multiproteicos/química , Complexos Multiproteicos/genética , Fenótipo , Homologia de Sequência de Aminoácidos , Síndrome , Adulto Jovem , beta Catenina/química , beta Catenina/metabolismo
20.
Pest Manag Sci ; 70(10): 1514-23, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24272923

RESUMO

BACKGROUND: The whitefly Bemisia tabaci (Gennadius) is a complex of cryptic species, some of which, namely the Mediterranean (MED) and the Middle East-Asia Minor 1 (MEAM1), are highly invasive and injurious crop pests worldwide and able to displace local genotypes. Invasiveness of B. tabaci may depend on the phenotype of inherited bacterial endosymbionts. Here, the B. tabaci genetic diversity variation that has occurred in recent years in southern Italy was examined. Whitefly was genotyped by restriction fragment length polymorphism analysis of polymerase-chain-reaction-amplified fragments (PCR-RFLP) of the COI gene and molecular identification of endosymbionts. Possible factors leading to the observed genetic diversity were examined. RESULTS: Q1 and Q2 mitochondrial types of MED, the only species found, coexisted in the field, while MEAM1 disappeared. A large spreading of Q2 (70% of individuals) was observed for the first time in Italy. Q2 showed a significant female-biased sex ratio and largely outnumbered Q1 on solanaceous hosts, in greenhouses and on insecticide-treated plants. Q1, with an even sex ratio, slightly prevailed on non-solanaceous hosts, especially on wild and untreated plants. Endosymbiont composition was associated with the mitochondrial type. Hamiltonella and Rickettsia were found at near fixation in Q1 and Q2 respectively; Arsenophonus, Cardinium and Wolbachia were found in both types, although at different frequencies. CONCLUSIONS: Q2 invasion seems to have been favoured by the agroecological conditions of southern Italy and by the female-biased sex ratio. Endosymbionts may have a role in Q2 invasiveness, acting as sex-ratio manipulators (e.g. Rickettsia) and possibly by benefiting the host fitness.


Assuntos
Bactérias/genética , Bactérias/isolamento & purificação , Hemípteros/genética , Hemípteros/microbiologia , Mitocôndrias/genética , Razão de Masculinidade , Simbiose , Animais , Feminino , Variação Genética , Espécies Introduzidas , Itália , Masculino , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...